Two Decades Later Cancer Vaccine Trial Shows Remarkable Long Term Survival

A landmark follow up study of an early breast cancer vaccine trial has revealed that all original participants remain alive twenty years after receiving the experimental immunotherapy, offering encouraging evidence that cancer vaccines may create long lasting immune protection against tumour recurrence. Researchers found that the vaccine trained the immune system to recognise specific cancer associated proteins, generating durable immune memory that continued to suppress tumour growth decades later, suggesting that preventive or therapeutic cancer vaccines could one day complement surgery chemotherapy and radiation by reducing relapse risk and strengthening long term survival. Scientists say the findings highlight the growing potential of personalised immunotherapy approaches that harness the body's own defences to fight cancer, marking an important step toward next generation treatments designed not only to treat disease but to prevent its return.